TABLE 2.
Incidence rate ratio (IRR) of SARS-CoV-2 from a Poisson regression analysis including age, country of residence, sex, vaccination status, and virus variant among people with PCD included in the COVID-PCD study, n = 62 (Switzerland, 2022).
| Unadjusted IRR | 95% CI | Fully adjusted IRR | 95% CI | |
|---|---|---|---|---|
| Age | ||||
| 0–14 years | Reference | |||
| 15–49 years | 0.34 | 0.19–0.60 | 0.42 | 0.21–0.85 |
| 50 years or older | 0.35 | 0.17–0.72 | 0.39 | 0.17–0.92 |
| Country | ||||
| United Kingdom | Reference | |||
| United States | 0.44 | 0.17–1.10 | 0.52 | 0.21–1.32 |
| Germany | 0.73 | 0.35–1.54 | 0.46 | 0.21–1.03 |
| Other European countries | 0.63 | 0.34–1.54 | 0.58 | 0.31–1.08 |
| Other non-European countries | 0.73 | 0.25–2.16 | 0.57 | 0.17–1.94 |
| Sex | ||||
| Male | Reference | |||
| Female | 0.74 | 0.45–1.22 | 0.91 | 0.54–1.55 |
| Vaccination a | ||||
| Not fully vaccinated | Reference | |||
| Fully vaccinated | 1.16 | 0.68–1.96 | 0.62 | 0.29–1.34 |
| Dominant virus variant period | ||||
| Original strain | Reference | |||
| Alpha | 2.63 | 1.12–6.14 | 2.69 | 1.14–6.36 |
| Delta | 3.74 | 1.70–8.22 | 4.52 | 1.92–10.64 |
| Omicron | 9.23 | 4.11–20.7 | 13.28 | 5.22–33.81 |
a
Full protection after vaccination defined as 14 days after second vaccination with vaccines requiring two shots (e.g., Pfizer, Moderna, AstraZeneca) or 14 days after vaccines requiring one shot (e.g., Janssen/Johnson and Johnson).